

Date 02/04/2025  
 Your Ref  
 Our Ref 9809

Enquiries to Richard Mutch  
 Extension 35687  
 Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

**FREEDOM OF INFORMATION – CANCER PRESCRIBING**

I write in response to your request for information in relation to cancer prescribing.

Question:

1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	343
1.2 Apalutamide (Erleada)	5
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	5
1.4 Darolutamide (Nubeqa)	19
1.5 Enzalutamide (Xtandi)	179
1.6 Talazoparib (Talzenna)	5<
1.7 Docetaxel	77

Question:

2. How many patients were treated with these products specifically for **prostate cancer** (ICD-10 code = C61) in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	18
2.2 Olaparib (Lynparza) for prostate cancer	0
2.3 Talazoparib (Talzenna) for prostate cancer	0

Headquarters  
 Mainpoint  
 102 West Port  
 Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
 Chief Executive Professor Caroline Hiscox  
 Lothian NHS Board is the common name of Lothian Health Board



Question:

3. How many patients were treated with the following combinations in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
3.1 Darolutamide (Nubeqa) + Docetaxel + ADT	5<
3.2 Olaparib (Lynparza) + Abiraterone	0

*Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide*

Question:

4. How many patients received the following products for **non-metastatic hormone sensitive prostate cancer** in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
4.1 Abiraterone	55
4.2 Enzalutamide	46

Question:

5. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
5.1 Nivolumab (Opdivo)	60
5.2 Nivolumab/Relatlimab (Opdualag)	0

Question:

6. How many patients were treated with **Nivolumab (Opdivo)** for the following diagnoses in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-months for which data are available?

Answer:

Diagnosis	Number patients treated
6.1 Malignant melanoma (ICD-10 codes = C43*, C44*, D03*, D485)	36

6.2 Lung Cancer ( <i>ICD-10 codes = C34*, C780</i> )	5<
6.3 Mesothelioma ( <i>ICD-10 codes = C45*, C384, C782</i> )	13
6.4 Renal Cell Carcinoma ( <i>ICD-10 codes = C64*, C65*, C790, D410</i> )	29
6.5 Oesophageal or Gastro-Oesophageal Junction ( <i>ICD-10 codes = C15*</i> )	30
6.6 Hodgkin Lymphoma ( <i>ICD-10 codes = C81*</i> )	0
6.7 Head and Neck Cancer ( <i>ICD-10 codes = C00 to C14, C30 to C32, C760, C770</i> )	22
6.8 Urothelial Carcinoma ( <i>ICD-10 codes = C67*</i> )	13 (Carcinoma of the Bladder Adjuvant Post O?)
6.9 Colorectal Cancer ( <i>ICD-10 codes = C18 to C20</i> )	0

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.



FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive